Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
XGN 
Exagen Inc (XGN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: XGN (3-star) is a STRONG-BUY. BUY since 14 days. Profits (26.52%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $11.17
1 Year Target Price $11.17
| 5 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 46.44% | Avg. Invested days 29 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 205.62M USD | Price to earnings Ratio - | 1Y Target Price 11.17 |
Price to earnings Ratio - | 1Y Target Price 11.17 | ||
Volume (30-day avg) 6 | Beta 1.62 | 52 Weeks Range 2.38 - 9.79 | Updated Date 08/15/2025 |
52 Weeks Range 2.38 - 9.79 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.89 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-07-29 | When - | Estimate -0.15 | Actual -0.21 |
Profitability
Profit Margin -28.85% | Operating Margin (TTM) -15.29% |
Management Effectiveness
Return on Assets (TTM) -16.24% | Return on Equity (TTM) -87.94% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 200795025 | Price to Sales(TTM) 3.49 |
Enterprise Value 200795025 | Price to Sales(TTM) 3.49 | ||
Enterprise Value to Revenue 3.41 | Enterprise Value to EBITDA -0.16 | Shares Outstanding 22003600 | Shares Floating 13603311 |
Shares Outstanding 22003600 | Shares Floating 13603311 | ||
Percent Insiders 19.64 | Percent Institutions 45.88 |
Upturn AI SWOT
Exagen Inc
Company Overview
History and Background
Exagen Inc. was founded in 2002 and is based in Vista, California. The company focuses on rheumatology diagnostics, developing and commercializing innovative testing solutions for autoimmune diseases.
Core Business Areas
- Diagnostic Testing: Exagen provides diagnostic and monitoring testing services for rheumatological diseases. These tests help physicians diagnose and manage conditions like rheumatoid arthritis, lupus, and systemic sclerosis.
Leadership and Structure
The leadership team includes John Aballi (President and CEO). The organizational structure is typical of a publicly traded company with departments for research and development, sales and marketing, operations, and finance.
Top Products and Market Share
Key Offerings
- AVISE CTD: A diagnostic test for connective tissue diseases. While exact market share is difficult to determine, Exagen holds a significant position in the rheumatology diagnostic market. The test provides information on the presence of autoantibodies associated with CTDs. Competitors include companies offering similar antibody testing services, such as Labcorp (LH) and Quest Diagnostics (DGX).
- AVISE SLE: A diagnostic test specifically for Systemic Lupus Erythematosus (SLE). Market share data for this specific test is proprietary, but Exagen is a key player. The test helps in diagnosing and monitoring lupus activity. Competitors include Labcorp (LH) and Quest Diagnostics (DGX).
Market Dynamics
Industry Overview
The rheumatology diagnostics market is growing due to the increasing prevalence of autoimmune diseases and the need for accurate and timely diagnosis.
Positioning
Exagen is positioned as a specialist in rheumatology diagnostics, focusing on innovative and proprietary testing solutions. Its competitive advantage lies in its specialized expertise and focused product portfolio.
Total Addressable Market (TAM)
The total addressable market for rheumatology diagnostics is estimated to be in the billions of dollars annually. Exagen is positioned to capture a significant portion of this market through its specialized tests.
Upturn SWOT Analysis
Strengths
- Specialized expertise in rheumatology diagnostics
- Proprietary and innovative testing solutions
- Established relationships with rheumatologists
- Strong focus on research and development
Weaknesses
- Reliance on reimbursement rates from payers
- Limited product portfolio compared to larger diagnostic companies
- Smaller scale compared to competitors like Labcorp and Quest
Opportunities
- Expanding product portfolio to cover additional autoimmune diseases
- Increasing adoption of precision medicine approaches
- Strategic partnerships with pharmaceutical companies
- Geographic expansion into new markets
Threats
- Changes in reimbursement policies
- Competition from larger diagnostic companies with broader test menus
- Technological advancements rendering current tests obsolete
- Economic downturn affecting healthcare spending
Competitors and Market Share
Key Competitors
- LH
- DGX
Competitive Landscape
Exagen's advantage lies in its specialization and innovative tests, but it faces competition from larger, more diversified companies with greater resources and broader market reach.
Growth Trajectory and Initiatives
Historical Growth: Analyze the growth over the past years.
Future Projections: Future growth is projected to be driven by increased adoption of its diagnostic tests and expansion into new markets and tests.
Recent Initiatives: Highlight recent strategic initiatives undertaken by Exagen Inc.
Summary
Exagen is a specialized rheumatology diagnostics company with innovative testing solutions. Its focus and expertise provide a competitive edge, but its smaller size and reliance on reimbursement rates present challenges. Future growth depends on expanding its product portfolio and increasing market penetration while navigating a competitive landscape and regulatory environment.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings (SEC)
- Industry Reports
- Analyst Reports
Disclaimers:
This analysis is based on publicly available information and represents a general overview. It is not financial advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Exagen Inc
Exchange NASDAQ | Headquaters Vista, CA, United States | ||
IPO Launch date 2019-09-19 | CEO, President & Director Mr. John Aballi | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 209 | Website https://www.exagen.com |
Full time employees 209 | Website https://www.exagen.com | ||
Exagen Inc. designs, develops, and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of complex rheumatic, and autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus platform, a cornerstone of the SLE assessment that begins by quantifying the level of CB-CAPs biomarkers (EC4d and BC4d) in the patient's blood; and AVISE APS that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE Anti-Histone, a test for autoantibodies to histone proteins; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; and AVISE Anti-CarP, a biomarker-driven RA prognostic test. Further, the company offers AVISE SLE Monitor, a blood test that employs CB-CAPs technology; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop T-Cell biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.